BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Luna M, Kamariski M, Principi I, Bocanegra V, Vallés PG. Severely ill pediatric patients with Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS) who suffered from multiple organ involvement in the early stage. Pediatr Nephrol 2021;36:1499-509. [PMID: 33205220 DOI: 10.1007/s00467-020-04829-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Balestracci A, Capone MA, Meni Battaglia L, Toledo I, Martin SM, Beaudoin L, Balbaryski J, Gómez L. Erythropoietin in children with hemolytic uremic syndrome: a pilot randomized controlled trial. Pediatr Nephrol 2022. [PMID: 35166922 DOI: 10.1007/s00467-022-05474-9] [Reference Citation Analysis]
2 Henrique IDM, Sacerdoti F, Ferreira RL, Henrique C, Amaral MM, Piazza RMF, Luz D. Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives. Front Cell Infect Microbiol 2022;12:825856. [DOI: 10.3389/fcimb.2022.825856] [Reference Citation Analysis]
3 Palma LMP, Vaisbich-Guimarães MH, Sridharan M, Tran CL, Sethi S. Thrombotic microangiopathy in children. Pediatr Nephrol 2022. [PMID: 35041041 DOI: 10.1007/s00467-021-05370-8] [Reference Citation Analysis]
4 Álvarez RS, Gómez FD, Zotta E, Paton AW, Paton JC, Ibarra C, Sacerdoti F, Amaral MM. Combined Action of Shiga Toxin Type 2 and Subtilase Cytotoxin in the Pathogenesis of Hemolytic Uremic Syndrome. Toxins (Basel) 2021;13:536. [PMID: 34437406 DOI: 10.3390/toxins13080536] [Reference Citation Analysis]